The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
12h
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback